Objectives: To evaluate whether protein and energy supplementation influences recovery after hip fracture. Design: Systematic review of randomised and quasi-randomised trials in people aged 65 y and over. Data sources: We searched seven electronic databases from 1966 to April 2002, four journals and reference lists of relevant articles. We contacted trial investigators and experts for details of other trials. Main outcome measures: Mortality, complications and unfavourable outcome (mortality or survivors with complications) were the primary outcomes. We also sought data on length of hospital stay, functional status after hip fracture, quality of life and compliance with supplementation. Results: In total, 12 randomised trials involving 898 participants were included. Nine trials evaluated protein and energy supplementation (five oral and four nasogastric feeding), and a further three trials tested oral protein supplementation. Potential biases resulting from inadequate allocation concealment and lack of assessor blinding and intention-to-treat analysis, as well as the limited outcome data, mean that the results must be interpreted with caution. Pooled data from eight of the nine trials evaluating protein and energy supplements showed no evidence for an effect on mortality (relative risk 0.92, 95% CI 0.56-1.50). Limited data from only three trials showed that oral protein and energy supplements may reduce unfavourable outcome (relative risk 0.52, 95% CI 0.32-0.84). Conclusion: Based on limited evidence, oral protein and energy supplementation after hip fracture may reduce unfavourable outcome. Further evidence from good-quality randomised trials is required to inform clinical practice.
Introduction
Mortality 1 y after hip fracture varies from 14 to 37% (Lyons, 1997) . Acute hospital costs after hip fracture are substantial, and costs of rehabilitation and care in the community may be greater; respectively, estimated at d4800 and d7500 at 1995/6 prices in the UK (Dolan & Torgerson, 1998) . Figures from Belgium covering a similar period showed average costs of an acute hospital stay at A8667, with extra costs compared with non-hip fracture controls of A6636 in the year after hospitalisation (Autier et al, 2000) .
People with hip fractures, who are often under-nourished at the time of the fracture (Mansell et al, 1990; Lumbers et al, 1996; Maffulli et al, 1999) , have poor food intakes in hospital (Bastow et al, 1983a; Jallut et al, 1990; Patterson et al, 1992; Lumbers et al, 1999) . Under-nutrition leads to mental apathy, reduced muscle power, and impaired cardiac function and immunity (Keys et al, 1950; Lesourd, 1997) ; these increase the tendency to develop postoperative complications and hinder recovery. Prolonged rehabilitation and increased risk of death after hip fracture are associated with under-nutrition (Bastow et al, 1983a; Lumbers et al, 1996) .
We evaluated whether protein and energy supplementation of people with hip fracture affects the outcome, by examining the evidence from randomised controlled trials.
Methods

Search strategy
We identified relevant randomised and quasi-randomised trials in any language (see Table 1 for eligibility details) by electronic searching of seven databases, hand searching of four nutrition journals, checking of reference lists of reported trials and review articles, and contacting trialists and other experts. Our most recent search was concluded in April 2002. Full details of our search strategy are available ).
Assessment of eligibility and trial quality
Both reviewers independently assessed reports for predefined eligibility and methodological quality (see Table 1 ). Differences in opinion were resolved by discussion. We included published and unpublished trials, whether available in full or abstract only. Authors of articles were contacted for further details of their trials.
Outcomes assessed
We sought data on all-cause mortality, numbers of participants with complications (as defined by the investigators), and lengths of acute hospital and rehabilitation unit stay.
Where possible, the numbers of patients with 'unfavourable outcome' have been presented; this is defined as the sum of the patients who died plus survivors with complications. However, we also accepted the slightly different definition of 'unfavourable outcome' (mortality or survivors with a major complication or two or more minor complications) used in three trials (Delmi et al, 1990; Tkatch et al, 1992; Hankins, 1996) . In these trials bedsores, pneumonia, pyelonephritis, severe anaemia, deep vein thrombosis, acute renal failure, pulmonary embolism and heart failure were defined as 'major complications'.
Data extraction and synthesis
Data and trial information were independently extracted by each of us and, upon resolving any discrepancies, the final data set was entered into Review Manager version 4.1. (Oxford, England: The Cochrane Collaboration, 2000) . For each study, relative risks and 99% confidence limits were calculated for dichotomous outcomes. Where appropriate, the data from comparable groups of trials were combined using the fixed effect model, and results presented with 95% confidence limits. In the meta-analyses, the weight given to each study was the inverse of its variance, ie more precise estimates (from larger studies with more events) were given more weight. Heterogeneity between trials was tested using a standard w 2 test. Subgroup and sensitivity analyses, based on the feeding route (oral, enteral or parenteral), pre-existing nutritional status and aspects of methodology, were planned from the outset and undertaken where appropriate. This review is derived from a regularly updated review on all forms of nutritional supplementation after hip fracture published in The Cochrane Library ). Mortality results have been presented using denominators based on the numbers of participants at randomisation (intention-to-treat-analysis). 
Results
We found 12 eligible studies, involving 898 participants (Bastow et al, 1983b; Stableforth, 1986; Delmi et al, 1990; Brown & Seabrook, 1992; Gallagher et al, 1992; Tkatch et al, 1992; Madigan, 1994; Hankins, 1996; Hartgrink et al, 1998; Schurch et al, 1998; Sullivan et al, 1998; Espaulella et al, 2000) . Details of the trials are provided in Table 2 . Nine tested a combination of protein and energy supplementation (the route was oral in five and by nasogastric tube in four). Three trials tested oral protein supplementation. Where reported, the mean age of participants was usually over 80 y. Many of the studies excluded patients with medical conditions (dementia, stroke, endocrine disease, cancer, kidney or liver failure). Six trials failed to provide any nutritional assessment of trial participants by anthropometry, for example, weight or mid-arm circumference (Delmi et al, 1990; Gallagher et al, 1992; Tkatch et al, 1992; Hartgrink et al, 1998; Sullivan et al, 1998; Espaulella et al, 2000) . Four studies specifically examined nutritional supplementation in malnourished participants, each study assessing nutritional status differently; three used anthropometric criteria (Bastow et al, 1983b; Brown & Seabrook, 1992; Hankins, 1996; ) and one used serum albumin values (Gallagher et al, 1992) .
The quality of reported trial methodology was disappointing. Concealment of allocation was adequate in only three trials (Hankins, 1996; Sullivan et al, 1998; Espaulella et al, 2000) . Intention-to-treat analysis was carried out in four studies (Bastow et al, 1983b; Brown & Seabrook, 1992; Hankins, 1996; Sullivan et al, 1998) . In three studies, participants were excluded after randomisation because of poor compliance with dietary supplementation (Tkatch et al, 1992; Madigan, 1994; Espaulella et al, 2000) . Data on some of these participants were obtained for two studies (Madigan, 1994; Espaulella et al, 2000) .
Only two studies (Brown & Seabrook, 1992; Espaulella et al, 2000) reported blinding of outcome assessors. While being difficult for nasogastric feeding, blinded assessment should be possible for other interventions, and after discharge from hospital. Blinding of both participants and treatment providers was reported in only one study (Espaulella et al, 2000) .
Inclusion and exclusion criteria were well defined in all trials. Eight studies (Delmi et al, 1990; Tkatch et al, 1992; Madigan, 1994; Hankins, 1996; Hartgrink et al, 1998; Schurch et al, 1998; Sullivan et al, 1998; Espaulella et al, 2000) gave clear details of the exact nutritional content, and of the protocol for application, of the supplement. Comparable care programmes, other than the trial interventions, were confirmed in three trials (Stableforth, 1986; Hartgrink et al, 1998; Espaulella et al, 2000) .
Follow-up of trial participants was generally active and appropriate in terms of outcome assessment. However, only five studies followed participants up for 6 months or more (Delmi et al, 1990; Tkatch et al, 1992; Schurch et al, 1998; Sullivan et al, 1998; Espaulella et al, 2000) , and no study reported patients' perceived quality of life after discharge. Economic outcomes were also not reported.
Postoperative complications were reported as a wide variety of individual conditions (including diarrhoea, nausea, vomiting, aspiration pneumonia, gastrointestinal ulcer, pressure sore, face flushing, chest infection, urinary tract infection, deep venous thrombosis, pulmonary embolism, cardiac failure, anaemia, confusion and acute renal failure) and generic conditions (gastrointestinal, surgical, infection, postoperative, life-threatening) . The definition of complications was consistent in three trials (Delmi et al, 1990; Tkatch et al, 1992; Hankins, 1996) , but varied in definition and scope in the rest.
Lengths of hospital stay in acute and rehabilitation hospitals were often reported, but have not been presented in this paper. Such data may be misleading for two main reasons. Firstly, this outcome, while important from the costs perspective, is a poor indicator of patient health; administrative procedures are often more influential. Secondly, even when means and standard deviations (s.d.) for these outcomes have been reported, it is unlikely that lengths of stay were normally distributed. A comprehensive account of length of stay results is available elsewhere ). Suffice to record here that we found no consistent pattern in the results that could be relied upon to draw conclusions of relative effect.
Protein and energy supplementation Protein and energy supplementation was supplied orally in five studies (Stableforth, 1986; Delmi et al, 1990; Brown & Seabrook, 1992; Madigan, 1994; Hankins, 1996) of which two (Brown & Seabrook, 1992; Hankins, 1996) targeted malnourished patients. Four studies evaluated nasogastric supplementation (Bastow et al, 1983b; Gallagher et al, 1992; Hartgrink et al, 1998; Sullivan et al, 1998) of which two (Bastow et al, 1983b; Gallagher et al, 1992) targeted malnourished patients. No data were available for pooling from one trial (Gallagher et al, 1992) published as an abstract only.
Overall mortality (Figure 1 ) was similar in the intervention and control groups (relative risk 0.92, 95% CI 0.56-1.50). There was marginally significant heterogeneity (Po0.1). There was no evidence of an effect for mortality when split by feeding route (Figure 1 ). There was however considerable heterogeneity (P ¼ 0.04) for the mortality results from the three nasogastric feeding trials. All seven deaths in one trial (Hartgrink et al, 1998) occurred in the intervention group during the 2-week period of observation. This could have been because of chance, as the deaths were not obviously related to tube feeding or aspiration pneumonia, a complication of tube feeding. Conversely, the five deaths in the control group in another trial (Sullivan et al, 1998) might in part reflect the greater frailty of this group at recruitment.
When trials were subgrouped according to nutritional status, mortality tended to be reduced in the supplemented Protein and energy supplementation for hip fracture A Avenell and HHG Handoll groups of those trials that targeted malnourished participants (relative risk 0.61, 95% CI 0.28-1.34) but not in the other trials (relative risk 1.20, 95% CI 0.63-2.28). However, a test of interaction showed that the difference in the results of the two groups of trials was not statistically significant (P ¼ 0.2).
Pooled data from four trials for patients with complications tended to favour supplementation (relative risk of 0.68, 95% CI 0.43-1.06) (Figure 2 ). However, there was significant heterogeneity (P ¼ 0.05), which reflected the different results of the only nasogastric trial (Sullivan et al, 1998) . Combined results (Figure 2 ) from the three oral feeding studies (Stableforth, 1986; Delmi et al, 1990; Hankins, 1996; ) showed a reduction, of borderline statistical significance, in participants with complications at final follow-up in the supplemented group (relative risk 0.50, 95% CI 0.25-1.00).
The results for unfavourable outcome (mortality or complications) were only available for three oral supplementation trials (Stableforth, 1986; Delmi et al, 1990; Hankins, 1996) . Pooled data from these trials gave a statistically significant result (Figure 3 ), in favour of the supplemented group, at final follow-up (relative risk 0.52, 95% CI 0.32-0.84). However, an exploratory analysis based on numbers randomised (in which it was assumed that all excluded participants in the supplemented group had complications at follow-up) showed the care that should be Methodological rating for concealment of randomisation: A, method did not allow disclosure of assignment; B, small, but possible chance of disclosure of assignment, or states 'random' but no description given; C, quasi-randomised (alternate allocation to groups). a Where nasogastric or oral supplements were given, patients were always allowed the normal ward diet.
Protein and energy supplementation for hip fracturetaken when viewing results from small trials. Both the results for complications (relative risk 0.70, 95% CI 0.37-1.34) and unfavourable outcome (relative risk 0.67, 95% CI 0.42-1.05) were no longer statistically significant. One oral feeding study (Hankins, 1996) found no statistically significant effect of the supplement at 2 months on the Barthel Index of functional ability. The greater tendency to return to premorbid mobility of supplementation group participants in another oral feeding study (Madigan, 1994) may reflect that more supplemented participants were sent to a rehabilitation hospital. Physiotherapy goals were achieved more quickly in the intervention groups in one nasogastric feeding study (Bastow et al, 1983b) . A second nasogastric feeding study (Sullivan et al, 1998) showed no statistically significant difference between intervention and control groups for activities of daily living at discharge.
No problems were reported for compliance in one oral feeding study (Delmi et al, 1990) ; whereas 35% of patients did not complete the course in another oral study (Hankins, 1996) . Only 26% of the intervention group tolerated feeding for the full 2 weeks in one nasogastric feeding trial (Hartgrink et al, 1998) , whereas 78% tolerated nasogastric feeding until discharge from the ward in another (Bastow et al, 1983b) . Although 18 participants of the intervention group developed diarrhoea in the trial by Bastow et al (1983b) , this was ascribed mainly to antibiotics; no information was provided on gastrointestinal complications for the control group. Sullivan et al (1998) reported that there was no feed-induced diarrhoea from nasogastric feeding, but three participants in the intervention group had bloating in the early morning.
Volitional food intake was not significantly affected by supplementation in three oral feeding studies (Delmi et al, 1990; Madigan, 1994; Hankins, 1996) and one nasogastric feeding study (Sullivan et al, 1998) . Another trial (Bastow et al, 1983b) found that nasogastric feeding significantly suppressed oral intake in thin, but not very thin patients.
Effect of protein-only supplement
Three studies (Tkatch et al, 1992; Schurch et al, 1998; Espaulella et al, 2000) investigated whether approximately 20 g of protein in a supplement influenced the outcome from hip fracture. The studies failed to carry out intention-to-treat analyses for all outcomes. No significant effect on mortality (Figure 4 ) could be demonstrated (relative risk 1.38, 95% CI 0.82-2.34).
An unfavourable outcome was significantly reduced by protein supplementation in two trials ( Figure 5 ) (relative risk 0.78, 95% CI 0.65-0.95). However, the results for one study (Espaulella et al, 2000) should be viewed in the context of the greater number of deaths in the protein supplementation group. No significant differences between intervention and control groups, at 6 months follow-up, were reported in one study (Espaulella et al, 2000) for mobility or Barthel Index scores, and in another study (Schurch et al, 1998) for activities of daily living.
Discussion
This review found limited evidence from 12 small trials testing the effectiveness of nutritional supplementation after hip fracture. Flawed study design, including the exclusion of participants for poor compliance and short duration of follow-up with insufficient ascertainment of important outcomes, also compromises the quality of the available evidence. While we acknowledge the particular difficulties in conducting randomised controlled trials in frail, elderly patients, it remains important to undertake intention-totreat analysis to examine the effectiveness of supplementation in the real world.
Combining data for protein and energy supplementation studies reveals no clear benefit in terms of mortality or patients with complications. There is no firm evidence that malnourished patients are more likely to benefit from protein and energy supplementation than those who are not malnourished. This could result from the variation in definition of malnutrition and insufficient numbers.
Oral protein and energy supplementation appears to reduce the number of patients with complications and unfavourable outcomes. However, this is based on three small studies, and the largest study (Delmi et al, 1990) did not account for all the participants randomised.
No clear effect of nasogastric feeding is evident. The high mortality in the intervention group in one trial (Hartgrink et al, 1998) is unexplained.
There is weak evidence that including protein in the supplement improves rehabilitation. However, the higher mortality in the supplemented group in one study (Espaulella et al, 2000) is unexplained, and the three studies failed to account for all patients.
Inability to tolerate nasogastric tubes and problems with palatability of oral feeds were common problems. Since malnutrition produces mental apathy (Keys et al, 1950) , this may further reduce supplement intake. Ensuring increased nutritional intake has major implications for hospital service provision, and has ethical implications when the patient is unwilling to feed or to tolerate nasogastric feeding.
Nasogastric feeding allowed the provision of higher energy intakes in these studies (3.9-6.3 MJ/day, or 900-1500 kcal/ day). Oral supplements provided under 1.7 MJ/day (400 kcal) Protein and energy supplementation for hip fracture A Avenell and HHG Handoll daily. Nasogastric feeding, which potentially has more risk of complications, is likely to be targeted at those requiring higher levels of supplementation. Attempts to overcome the poor compliance with oral supplements, include specially fortified hospital meals, the provision of frequent small snacks, and small volume oral feeds prescribed with drug rounds (Gall et al, 1998; Stephen et al, 1998; Potter et al, 2001) . The provision of health-care assistants, specially trained to help all aspects of patients' feeding, is being evaluated in the care of acutely ill older patients (Hickson et al, 1999) .
In conclusion, there is some evidence of the effectiveness of nutritional supplementation for oral protein and energy feeds, but the evidence is weak. The benefits of nasogastric feeding are less certain, and it should probably be reserved for the very malnourished, with intakes unresponsive to oral supplementation.
Large, well-designed trials are needed of protein and energy supplementation after hip fracture. Such trials should examine the possible effect modification because of nutritional status, and consider the quality of life and cost issues over at least 1 y after hip fracture.
